subscribeSubscribe
price-trendAsk Us
BridgeBio presents detailed +ve results from Ph3 ATTRibute-CM study acoramidis

BridgeBio presents detailed +ve results from Ph3 ATTRibute-CM study acoramidis
GLOBENEWSWIRE
27 Aug 2023
Share Share
BridgeBio heart disease med vindicated with phase 3 victory

BridgeBio heart disease med vindicated with phase 3 victory
Max Bayer FIERCE BIOTECH
17 Jul 2023
Share Share
BridgeBio shares crash as their lead PhIII drug fails

BridgeBio shares crash as their lead PhIII drug fails
John Carroll ENDPTS
28 Dec 2021
Share Share